Outcomes over the First Two Years of Treatment with Mepolizumab in Severe Asthma

This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.https://bit.ly/3ChWN63